Short answer · Medically reviewed summary · Last updated: 2026-04-06
The most promising research in Ehlers-Danlos syndromes (EDS) is currently focused on identifying the genetic underpinnings of the hypermobile type (hEDS) and developing targeted therapies to manage the systemic complications associated with vascular and classical subtypes. Current Research Directions While the genetic cause for the most common form, hEDS, remains elusive, large-scale genomic studies—such as the International EDS Consortium’s efforts—are actively mapping the human genome to identify candidate variants. For other types of Ehlers-Danlos, research is shifting toward understanding how extracellular matrix proteins influence tissue integrity.
13 people with Ehlers Danlos have shared their first-person experience on this question at DiseaseMaps.
What are the latest advances in Ehlers Danlos?
Latest advances in Ehlers Danlos: recent research, treatments in development and what they could mean, with sources.
The most promising research in Ehlers-Danlos syndromes (EDS) is currently focused on identifying the genetic underpinnings of the hypermobile type (hEDS) and developing targeted therapies to manage the systemic complications associated with vascular and classical subtypes.
Current Research Directions
While the genetic cause for the most common form, hEDS, remains elusive, large-scale genomic studies—such as the International EDS Consortium’s efforts—are actively mapping the human genome to identify candidate variants. For other types of Ehlers-Danlos, research is shifting toward understanding how extracellular matrix proteins influence tissue integrity. Scientists are also investigating the role of the microbiome and inflammatory biomarkers in managing the chronic pain and fatigue that significantly impact the quality of life for those with Ehlers-Danlos.
Recent Developments and Clinical Trials
Recent publications have underscored the heterogeneity of Ehlers-Danlos, leading to more refined diagnostic criteria. Clinical trials are currently exploring the efficacy of various pharmacological interventions for symptom management, including trials assessing the role of specific biologics for joint inflammation and cardiovascular monitoring for vascular Ehlers-Danlos. Although gene therapy for Ehlers-Danlos is still in the preclinical stage, advancements in CRISPR and mRNA technology offer long-term hope for correcting the underlying collagen synthesis errors.
How to Participate in Research
Patients can search for active studies at ClinicalTrials.gov by using the search term "Ehlers-Danlos syndrome." Engaging with organizations like The Ehlers-Danlos Society is also vital, as they maintain a registry that connects patients with researchers and clinical trial opportunities. Participation in these studies is the most effective way to accelerate the pace of medical discovery.
Medical Disclaimer: The information provided is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Research timelines are inherently unpredictable, and clinical trial results are not guaranteed.
References
- The Ehlers-Danlos Society (ehlers-danlos.com)
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet (orpha.net)
- ClinicalTrials.gov
Posted May 25, 2017 by Maria 2051
Posted May 27, 2017 by Jude 2050
Posted May 28, 2017 by Celi 2000
Posted May 31, 2017 by KathrynOConnor 2200
Posted Sep 27, 2017 by Lbond94 4100
Posted Oct 6, 2017 by Sasha 2050
Posted Oct 7, 2017 by Sharon 7050
Posted Oct 25, 2017 by Dolores 3050
Posted Jan 14, 2018 by stairphobe 3070
Posted Sep 29, 2019 by Amy 13500
Of the 14 subtypes of the group of connective tissue disorders known collectively as the Ehlers-Danlos syndromes (EDS), only the hypermobile type does not yet have identified genetic markers. Over 2019 and 2020, the HEDGE study will recruit, screen, and undertake genetic sequencing tests on 1000 individuals who have been diagnosed with hypermobile EDS by the most recent clinical criteria established in 2017.
The HEDGE study would not be possible without the EDS and Related Disorders Global Registry. Launched in July of 2018, the Global Registry is a collection of standardized health information provided by thousands of patients with all forms of EDS and hypermobility spectrum disorders (HSD), allowing researchers to compare and analyze patient data on a much larger scale than possible in individual research studies alone. The Registry has the potential to unlock countless discoveries about all forms of EDS and HSD and lays the groundwork for large-scale research efforts like the HEDGE study.
This study has Institutional Review Board oversight and approval by the Genetic Alliance (IORG0003358) IRB (IRB00003999). The Genetic Alliance Federal Wide Assurance number is: FWA00017292. Protocol EDS002 has been approved by the Genetic Alliance IRB (Federal registration number IORG0003358). Information can be found on this IRB by putting Genetic Alliance in the NAME search field on the Office of Human Research Protections website.
Posted Mar 11, 2020 by MegTheMariner 1870
Posted May 12, 2020 by Alex 3551
Posted Nov 19, 2021 by NuNu 2550
